10 March 2021 | News
The first agreement in Europe has been signed between the Russian government fund and ADIENNE Pharma & Biotech for the production of the Sputnik V vaccine in Italy
Photo Credit: CCIR (via sputnikvaccine.com)
The Italian-Russian Chamber of Commerce (CCIR) holds an aim of contributing to the development of economic, commercial, technical, legal, scientific and cultural collaboration between Italy and the Russian Federation as early as October 2020. CCIR with the support of Italian Embassy in Moscow has promoted meetings between Italian and European companies with Russian institutional counterparts to verify the opportunities in terms of cooperation relating to the production of the Russian Sputnik V vaccine in Italy.
The Italian associated company Adienne Srl, part of the multinational ADIENNE Pharma & Biotech founded with the support of the Italian-Russian Chamber of Commerce, has promoted a strategic agreement for the production in site of the Russian anticovid Sputnik V.
RDIF CEO Kirill Dmitriev confirmed that he has reached an agreement with the company ADIENNE Pharma & Biotech for the production of Sputnik V in Italy, signing the first European contract for the local production of the vaccine. The partnership will allow starting production as early as July 2021, the innovative production process will help create new jobs and will allow Italy to control the entire production process of the preparation. This will allow the production of 10 million doses by the end of the year.
Russian authorities are working on over 20 collaborative projects in Europe and the Sputnik V vaccine has already been registered in over 45 countries around the world. The Sputnik V vaccine in recent weeks has begun the review process by the European authorities that will allow the administration to citizens.